Wall Street Zen Downgrades Bioceres Crop Solutions (NASDAQ:BIOX) to Sell

Key Points

• Bioceres Crop Solutions has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, signaling a negative outlook for the stock.
• Oppenheimer has lowered its target price for Bioceres from $7.00 to $6.00 while maintaining an "outperform" rating, indicating mixed sentiments among analysts.
• The stock currently has a consensus rating of "Moderate Buy" with an average price target of $8.38, despite recent performance showing it opened at $3.47 with a market cap of $217.60 million.

Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday.

Separately, Oppenheimer cut their target price on Bioceres Crop Solutions from $7.00 to $6.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $8.38.

Bioceres Crop Solutions Price Performance

Shares of BIOX remained flat at $3.58 during midday trading on Friday. 151,581 shares of the stock were exchanged, compared to its average volume of 203,887. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.74 and a current ratio of 1.02. The business has a fifty day moving average price of $4.37 and a two-hundred day moving average price of $4.68. The firm has a market capitalization of $224.50 million, a P/E ratio of -25.57, a price-to-earnings-growth ratio of 1.48 and a beta of 0.44. Bioceres Crop Solutions has a fifty-two week low of $3.30 and a fifty-two week high of $11.41.

Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) last released its quarterly earnings data on Wednesday, May 21st. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.08. Bioceres Crop Solutions had a negative return on equity of 2.37% and a negative net margin of 2.14%. The business had revenue of $59.60 million for the quarter, compared to the consensus estimate of $61.80 million. On average, sell-side analysts forecast that Bioceres Crop Solutions will post -0.05 earnings per share for the current year.

Institutional Trading of Bioceres Crop Solutions

Several hedge funds and other institutional investors have recently made changes to their positions in BIOX. Jones Financial Companies Lllp lifted its holdings in shares of Bioceres Crop Solutions by 3,535.8% in the 1st quarter. Jones Financial Companies Lllp now owns 5,490 shares of the company's stock valued at $25,000 after buying an additional 5,339 shares during the period. Bank of America Corp DE increased its holdings in Bioceres Crop Solutions by 186.8% in the fourth quarter. Bank of America Corp DE now owns 5,735 shares of the company's stock valued at $35,000 after buying an additional 3,735 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Bioceres Crop Solutions during the 4th quarter worth approximately $72,000. Avanza Fonder AB acquired a new stake in shares of Bioceres Crop Solutions in the 1st quarter worth approximately $72,000. Finally, PDT Partners LLC purchased a new position in Bioceres Crop Solutions in the 1st quarter valued at approximately $81,000. Hedge funds and other institutional investors own 17.68% of the company's stock.

Bioceres Crop Solutions Company Profile

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.